Genprex (FRA:2DE1) Total Equity: €14.64 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2DE1 Genprex Inc FRA:2DE1
35 GF Score
Price €3.96
! 1 Warning Sign
View Full Analysis

What is Genprex Total Equity?

Genprex FRA:2DE1 35 Total Equity is €14.64 Mil as of Mar. 2026. GuruFocus rates FRA:2DE1 with a GF Score™ of 35/100. The stock has 1 warning sign investors should review.

Genprex's total equity for the quarter that ended in Mar. 2026 was €14.64 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Genprex Total Equity Historical Data

* Premium members only.

The historical data trend for Genprex's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genprex Total Equity Chart

Genprex Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.53 21.03 6.80 1.55 6.80

Genprex Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.58 1.21 0.65 6.80 14.64
FRA:2DE1
35GF Score
Genprex Inc FRA:2DE1
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genprex Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Genprex's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=8.676-1.876
=6.80

Genprex's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=17.565-2.92
=14.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €14.64 Mil mean?
Genprex (FRA:2DE1) has a Total Equity of €14.64 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Genprex and its competitors.
Is Genprex's Total Equity too high?
Genprex's current Total Equity is €14.64 Mil. Overall, Genprex has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Genprex's Total Equity compare to MLEC and LIMN?
Genprex's Total Equity of €14.64 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Genprex and its competitors. Genprex's current Total Equity is €14.64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genprex stock overvalued right now?
Genprex (FRA:2DE1) has a current Total Equity of €14.64 Mil. The current Total Equity is €14.64 Mil. Genprex's overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Genprex (FRA:2DE1), the current Total Equity is €14.64 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genprex Business Description

Other Exchanges GNPX:USA0A8I:UK
Address 3300 Bee Cave Road, Suite 650-227, Austin, TX, USA, 78746
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
35GF Score

Get the complete analysis for FRA:2DE1

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.96
Price